Oxaliplatin Pliva

Oxaliplatin, the active ingredient in Oxaliplatin Pliva, is a platinum coordination complex presented as a 100 mg/10 ml solution for intravenous use. It treats colorectal cancer and other gastrointestinal malignancies in adult patients. GNH USA supplies Oxaliplatin Pliva as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres and hospitals worldwide.

GNH USA supplies Oxaliplatin Pliva as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres and hospitals worldwide.

Oxaliplatin is a platinum‑based chemotherapy agent used in the treatment of cancers that arise from the gastrointestinal tract.

- Colorectal cancer: improves survival when combined with fluorouracil and leucovorin. - Gastric cancer: used in combination regimens for advanced disease. - Pancreatic cancer: part of multi‑drug protocols for metastatic disease.

Oxaliplatin may cause a range of adverse reactions, from mild to severe, that require monitoring during treatment.

Common Side Effects: - Nausea and vomiting: frequent gastrointestinal upset. - Peripheral neuropathy: tingling or numbness in the hands and feet. - Diarrhea: loose stools that may require supportive care. - Fatigue: generalized tiredness during therapy. - Myelosuppression: reduced blood cell counts.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Acute neurotoxicity: sudden onset of muscle cramps or difficulty breathing. - Thrombocytopenia: markedly low platelet counts increasing bleeding risk. - Neutropenic fever: fever with low neutrophil count indicating infection. - Renal impairment: decreased kidney function requiring dose adjustment.

When using Oxaliplatin, clinicians must assess patient suitability and monitor for toxicity throughout therapy.

- Renal function: assess baseline creatinine and adjust dose if impaired. - Hepatic function: monitor liver enzymes and bilirubin before each cycle. - Pre‑existing neuropathy: evaluate severity; avoid if grade ≥ 2. - Hematologic status: check complete blood count prior to infusion. - Concomitant ototoxic drugs: avoid combined use with other agents that affect hearing. - Store at ambient temperature: keep in original container, protect from light and moisture.

Oxaliplatin can interact with several medicines, altering efficacy or increasing toxicity.

Major Interactions (Avoid): - Nephrotoxic agents such as cisplatin or aminoglycosides: combined use heightens kidney damage risk. - High‑dose vitamin C: may reduce platinum‑DNA binding effectiveness.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin, heparin): increased bleeding tendency. - CYP450 inducers (rifampicin, carbamazepine): may affect plasma levels of co‑administered drugs. - NSAIDs: can worsen renal impairment when used with Oxaliplatin. - Immunosuppressants: heightened infection risk when combined with myelosuppression. - Proton pump inhibitors: may alter gastrointestinal absorption of supportive anti‑emetics.